The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels

被引:3
|
作者
Drouin-Chartier, Jean-Philippe [1 ]
Hogue, Jean-Charles [2 ]
Tremblay, Andre J. [1 ]
Bergeron, Jean [2 ]
Lamarche, Benoit [1 ]
Couture, Patrick [1 ,2 ]
机构
[1] Inst Nutr & Funct Foods INAF, Pavillon Serv, 2440 Hochelaga Blvd, Quebec City, PQ G1V 0A6, Canada
[2] Quebec Univ, CHU, Lipid Res Ctr, Laval, PQ, Canada
来源
关键词
Familial hypercholesterolemia; Apolipoprotein B-48; PCSK9; Atherosclerosis; LDL RECEPTOR GENE; CHYLOMICRON REMNANT CLEARANCE; SUBTILISIN/KEXIN TYPE 9; APOLIPOPROTEIN B-48; FRENCH-CANADIANS; PARTICLE-CHOLESTEROL; MUTATIONS; IDENTIFICATION; DEGRADATION; METABOLISM;
D O I
10.1186/s12944-017-0502-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Previous studies have reported high plasma concentrations of both intestinal apolipoprotein (apo) B-48-containing lipoproteins and PCSK9 in subjects with familial hypercholesterolemia (FH). However, the extent to which LDL receptor deficiency and PCSK9 levels influence plasma apoB-48 concentrations in humans remains to be fully characterized. The objective of the study was to assess the independent association between FH, PCSK9 concentrations and plasma apoB-48 levels in a large cohort of genetically defined FH heterozygotes (HeFH) and homozygotes (HoFH). Methods: A total of 118 HeFH, 6 HoFH, and 117 controls were included in the study. Plasma PCSK9 and apoB-48 concentrations were measured in the fasting state. Results: Plasma PCSK9 and apoB-48 levels were higher in FH subjects compared with controls (PCSK9: HoFH: 642. 6 +/- 246.9 vs. HeFH: 324.9 +/- 119.8 vs. controls: 194.5 +/- 65.9 ng/mL, P < 0.0001; apoB-48: HoFH: 14.71 +/- 4.36 vs. HeFH: 6.55 +/- 4.24 vs. controls: 3.03 +/- 2.07 mu g/mL; P < 0.0001). There were no correlations between apoB-48 and PCSK9 plasma levels in both controls (rho = 0.06, P = 0.5) and HeFH subjects (rho = 0.07, P = 0.4). Multiple linear regression analysis showed that the FH status was the only independent factor associated with apoB-48 levels, contributing to 28.7% of the variance (P < 0.0001). Conclusions: These data indicate that the elevation in plasma apoB-48 levels associated with FH is independent of PCSK9 levels.
引用
收藏
页数:8
相关论文
共 44 条
  • [21] Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
    Lupo, Maria Giovanna
    Arcidiacono, Diletta
    Zaramella, Alice
    Fimiani, Fabio
    Calabro, Paolo
    Cefalu, Angelo Baldassare
    Averna, Maurizio
    D'Erasmo, Laura
    Arca, Marcello
    De Martin, Sara
    Zambon, Alberto
    Ferri, Nicola
    ATHEROSCLEROSIS PLUS, 2021, 43 : 7 - 9
  • [22] PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
    Rogacev, Kyrill S.
    Heine, Gunnar H.
    Silbernagel, Guenther
    Kleber, Marcus E.
    Seiler, Sarah
    Emrich, Insa
    Lennartz, Simone
    Werner, Christian
    Zawada, Adam M.
    Fliser, Danilo
    Boehm, Michael
    Maerz, Winfried
    Scharnagl, Hubert
    Laufs, Ulrich
    PLOS ONE, 2016, 11 (01):
  • [23] TREATMENT WITH PCSK9 INHIBITORS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA LOWERS PLASMA LEVELS OF PLATELET ACTIVATING FACTOR AND ITS PRECURSORS: A COMBINED METABOLOMIC AND LIPIDOMIC APPROACH
    Di Minno, A.
    Calcaterra, I. L.
    Orsini, R.
    Chiesa, M.
    Cavalca, V.
    Anesi, A.
    Fiorelli, S.
    Eligini, S.
    Colombo, G.
    Donnarumma, S.
    Palermo, V.
    Tremoli, E.
    Porro, B.
    Di Minno, M. N. D.
    ATHEROSCLEROSIS, 2023, 379 : S63 - S64
  • [24] Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy
    Raal, Frederick
    Panz, Vanessa
    Immelman, Andrew
    Pilcher, Gillian
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (02):
  • [25] Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
    Almontashiri, Naif A. M.
    Vilmundarson, Ragnar O.
    Ghasemzadeh, Nima
    Dandona, Sonny
    Roberts, Robert
    Quyyumi, Arshed A.
    Chen, Hsiao-Huei
    Stewart, Alexandre F. R.
    PLOS ONE, 2014, 9 (09):
  • [26] Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach
    Di Minno, Alessandro
    Orsini, Roberta Clara
    Chiesa, Mattia
    Cavalca, Viviana
    Calcaterra, Ilenia
    Tripaldella, Maria
    Anesi, Andrea
    Fiorelli, Susanna
    Eligini, Sonia
    Colombo, Gualtiero, I
    Tremoli, Elena
    Porro, Benedetta
    Di Minno, Matteo Nicola Dario
    BIOMEDICINES, 2021, 9 (08)
  • [27] ANALYSIS OF THE LDLR, APOB, PCSK9 AND LDLRAP1 GENES VARIABILITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN WEST SIBERIA USING TARGETED HIGH THROUGHPUT RESEQUENCING
    Shakhtshneider, E.
    Ivanoshchuk, D.
    Orlov, P.
    Timoshchenko, O.
    Voevoda, M.
    ATHEROSCLEROSIS, 2019, 287 : E285 - E285
  • [28] Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study
    Toru Miyoshi
    Keigo Nakamura
    Masayuki Doi
    Hiroshi Ito
    American Journal of Cardiovascular Drugs, 2015, 15 : 213 - 219
  • [29] Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study
    Miyoshi, Toru
    Nakamura, Keigo
    Doi, Masayuki
    Ito, Hiroshi
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (03) : 213 - 219
  • [30] PCSK9 INHIBITORS ALTER THE DISTRIBUTION OF MACROPHAGEDERIVED CHOLESTEROL EFFLUX TO FAMILIAL HYPERCHOLESTEROLEMIA LIPOPROTEINS AND PROMOTE MACROPHAGE-SPECIFIC REVERSE CHOLESTEROL TRANSPORT IN VIVO
    Borras, C.
    Canyelles, M.
    Girona, J.
    Plana, N.
    Revilla, G.
    Llorente-Cortes, V.
    Kovanen, P. T.
    Jauhiainen, M.
    Lee-Rueckert, M.
    Arrieta, F.
    Martinez-Botas, J.
    Gomez-Coronado, D.
    Ribalta, J.
    Blanco-Vaca, F.
    Tondo, M.
    Escola-Gil, J. C.
    ATHEROSCLEROSIS, 2023, 379 : S62 - S62